Tianyu Co., Ltd. announced that its wholly-owned subsidiary Jingsheng Pharmaceutical's apatamine API recently passed the CDE review. This raw material is used to treat prostate cancer. The packaging specification is 25Kg/barrel, and the registration number is Y20240000773. The company submitted an application for registration in 2024 and was accepted. This active ingredient must obtain the “Meets Requirements” notice from the Zhejiang Drug Administration's GMP compliance inspection before it can be marketed and sold domestically. As of the announcement date, in addition to the company, 10 domestic manufacturers had passed the technical review. Currently, Jingsheng Pharmaceutical is preparing to apply for a GMP compliance inspection, and there is uncertainty about the launch time.

Zhitongcaijing · 5d ago
Tianyu Co., Ltd. announced that its wholly-owned subsidiary Jingsheng Pharmaceutical's apatamine API recently passed the CDE review. This raw material is used to treat prostate cancer. The packaging specification is 25Kg/barrel, and the registration number is Y20240000773. The company submitted an application for registration in 2024 and was accepted. This active ingredient must obtain the “Meets Requirements” notice from the Zhejiang Drug Administration's GMP compliance inspection before it can be marketed and sold domestically. As of the announcement date, in addition to the company, 10 domestic manufacturers had passed the technical review. Currently, Jingsheng Pharmaceutical is preparing to apply for a GMP compliance inspection, and there is uncertainty about the launch time.